Sunitinib 치료 중인 전이성 신세포암 환자에서 발생한저혈당성 혼수

We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia andmetabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renalcell carcinoma. Sunitinib-induced hypo...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of medicine pp. 501 - 504
Main Authors 조미영, 심혁, 박무림
Format Journal Article
LanguageKorean
Published 대한내과학회 01.10.2014
Subjects
내과학
Online AccessGet full text
ISSN1738-9364
2289-0769
DOI10.3904/kjm.2014.87.4.501

Cover

More Information
Summary:We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia andmetabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renalcell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due tosunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib. KCI Citation Count: 0
Bibliography:G704-000582.2014.87.4.012
ISSN:1738-9364
2289-0769
DOI:10.3904/kjm.2014.87.4.501